Ferring licenses Enteris Peptelligence to turn injectable into oral drug

By Dani Bancroft

- Last updated on GMT


Related tags Oral drug delivery Pharmacology

Ferring is the third company in a week which will use Enteris BioPharma’s Peptelligence engineering platform for small molecules to develop oral formulations.

Enteris BioPharma, Inc. in New Jersey, US, will also provide clinical trial finished product in exchange for milestone payments and royalties based on net sales.

Switzerland-based Ferring Pharmaceutcials Group is developing therapies for a range of indications, including reproductive health, Crohn’s disease and Prader-Willi Syndrome.  

Enteris’ proprietary Peptelligence platform has also been licensed out to two​ other biopharmas in the past 7 days to engineer peptide-based formulations into more orally bioavailable equivalents.

The specific product regarding this license deal, however, was not disclosed.

Joel Tune, CEO of Enteris, said “our Peptelligence platform [enhances] the market potential of peptide-based therapeutics by enabling the oral delivery of medications that must otherwise be administered by injection.”

Oral bioavailability

There are significant benefits of oral drug delivery over injections, including improved safety, patient compliance and ease of administration.

“The ability to deliver oral peptides offers Ferring the opportunity to provide additional therapeutic choices to patients,”​ explained Alan Harris, Senior VP and R&D Executive Office of Ferring Pharmaceuticals.

Enteris’ Peptelligence platform is based on encapsulation​ of the client’s active pharmaceutical ingredient (API) using two excipients to form an ingestible formulation.

These include a permeation enhancer to aid gut absorption and solubilize the API, and a second excipient - citric acid - which serves as a multifunction biochemical transporter.

“We are impressed with Enteris' proprietary oral delivery technology and look forward to working with them to advance this development program,"​ Harris added.

Ferring was unavailable for comment.

The Peptelligence platform (Image: Enteris Biopharma, Inc.)

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more